Latest Articles in biogen

Alzheimer's Drug From Biogen, Eisai Slows Cognitive Decline, Side-effects In Focus

The drug, lecanemab, was associated with a dangerous type of brain swelling in nearly 13 per cent of patients in the trial that spanned 18 months and enrolled nearly 1,800 participants with early-stage Alzheimer's

Read More

USFDA Extends Review Of Biogen's ALS Drug

Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for review and set a new target action date of April 25, 2023

Read More

Eisai, Biogen Say Alzheimer's Drug Slows Cognitive Decline

Eisai and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs

Read More

US Pharma Biogen Lands $900 Mn Settlement With Its Whistleblower

As per the statement released by the US Justice Department on Monday, Michael Bawduniak, the whistleblower behind the report, will receive about $250 million directly. The rest will essentially go to the federal government

Read More

ALS Drug Shows Clinical Benefit Says Biogen

The Biogen drug, tofersen, is currently under priority review by the U.S. Food and Drug Administration with an approval decision expected by Jan 25

Read More